What is Cosmo Pharmaceuticals NV Price-to-Operating-Cash-Flow?
As of today (2024-12-14), Cosmo Pharmaceuticals NV's share price is CHF60.10.
Cosmo Pharmaceuticals NV's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2024 was CHF6.97. Hence, Cosmo Pharmaceuticals NV's Price-to-Operating-Cash-Flow Ratio for today is 8.62.
The historical rank and industry rank for Cosmo Pharmaceuticals NV's Price-to-Operating-Cash-Flow or its related term are showing as below:
LTS:0RGI'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.71 Med: 59.47 Max: 214.41
Current: 8.71
During the past 13 years, Cosmo Pharmaceuticals NV's highest Price-to-Operating-Cash-Flow Ratio was 214.41. The lowest was 8.71. And the median was 59.47.
Cosmo Pharmaceuticals NV's Cash Flow from Operations per share for the
six
months ended in Jun. 2024 was CHF5.91.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2024 was CHF6.97.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Cosmo Pharmaceuticals NV was 219.30% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 26.60% per year.
During the past 13 years, Cosmo Pharmaceuticals NV's highest 3-Year average Operating Cash Flow per Share Growth Rate was 78.60% per year. The lowest was -27.90% per year. And the median was 26.60% per year.
Cosmo Pharmaceuticals NV Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Cosmo Pharmaceuticals NV's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo Pharmaceuticals NV Price-to-Operating-Cash-Flow Chart
|
Cosmo Pharmaceuticals NV Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
- |
87.63 |
84.54 |
30.66 |
25.85 |
|
Cosmo Pharmaceuticals NV Semi-Annual Data
|
|
Dec14 |
Jun15 |
Dec15 |
Jun16 |
Dec16 |
Jun17 |
Dec17 |
Jun18 |
Dec18 |
Jun19 |
Dec19 |
Jun20 |
Dec20 |
Jun21 |
Dec21 |
Jun22 |
Dec22 |
Jun23 |
Dec23 |
Jun24 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
30.66 |
- |
25.85 |
- |
Competitive Comparison of Cosmo Pharmaceuticals NV's Price-to-Operating-Cash-Flow
For the Drug Manufacturers - General subindustry, Cosmo Pharmaceuticals NV's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo Pharmaceuticals NV's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo Pharmaceuticals NV's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Cosmo Pharmaceuticals NV's Price-to-Operating-Cash-Flow falls into.
Cosmo Pharmaceuticals NV Price-to-Operating-Cash-Flow Calculation
Cosmo Pharmaceuticals NV's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 60.10 | / | 6.974 |
| = | 8.62 |
Cosmo Pharmaceuticals NV's Share Price of today is CHF60.10.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cosmo Pharmaceuticals NV's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2024 was CHF6.97.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Cosmo Pharmaceuticals NV Business Description
Traded in Other Exchanges
Address
Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.
Cosmo Pharmaceuticals NV Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0RGI has been successfully added to your